Privacy Policy

Login

Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Fredag 23 Maj | 06:41:16 Europe / Stockholm

Svenska | English

BioStock

Prenumeration

Biosergen advances antifungal drug with strong Q1 results

2025-05-21 15:47:00

Biosergen’s Q1 report highlights the successful completion of the second patient cohort in its BSG005 proof-of-concept clinical trial, targeting life-threatening fungal infections. CEO Tine Olesen describes the results as demonstrating real therapeutic potential, paving the way for the third cohort in Q4 2025. We reached out to Olesen for a comment.

Read the interview at biostock.se:

https://biostock.se/en/2025/05/biosergen-advances-antifungal-drug-with-strong-q1-results/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

BioStock

Prenumeration

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden